Locoregional approaches to therapy with gliomas as the paradigm

Current Opinion in Oncology

Volumn 10, Issue 3, 1998, Pages 201-206

  Liang, Bertrand C ^a   Weil, Michael ^b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; NIMUSTINE;

CANCER CHEMOTHERAPY; CANCER INFILTRATION; CANCER RADIOTHERAPY; GLIOBLASTOMA; HEARING LOSS; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; NAUSEA; NEUTRON CAPTURE THERAPY; PRIORITY JOURNAL; PROGNOSIS; RADIOSENSITIZATION; REVIEW; VOMITING;

EID: 0031860785     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199805000-00005     Document Type: Review

References (38)

1. Bailey P, Cushing H: A Classification of the Tumors of the Glioma Group on a Histogenetic Basis With a Correlated Study of Prognosis. Philadelphia: JB Lippincott; 1926:113-118.
2. Salazar OM, Rubin P: The spread of glioblastoma multiforme as a determining factor in the radiation treatment volume. Int J Radiol Oncol Biol Phys 1976, 1:627-637.
3. Burger PC, Dubois PJ, Schold SC, Smith KR, Odom GL, Crafts DC, Giangaspero F: Computerized tomographic and pathologic studies of the untreated, quiescent and recurrent glioblastoma multiforme. J Neurosurg 1983, 58:159-169.
4. Daumas-Duport C, Scheitauer BW, Kelly PJ: A histologic and cytologic method for the spatial definition of gliomas. Mayo Clin Proc 1987, 62:435-439.
5. Kelly PJ, Daumas-Duport C, Scheitauer BW, Kispert DB: Stereotactic histologic correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. Mayo Clin Proc 1987, 62:450-459.
6. Thomas DGT, Poweel MP, Bradford R, Darling JL, Olney J, Barnard RO: Correlation of CT directed target site with histology and cell culture in cerebral glioma. Appl Neurophysiol 1985, 48:460-462.
7. Halperin EC, Burger PC, Bullard DE: The fallacy of the localized supratentorial malignant glioma. Int J Radiat Oncol Biol Phys 1988, 15:505-509.
8. Hochberg FH, Pruitt A: Assumptions in the radiotherapy of glioblastoma. Neurology 1980, 30:907-911.
9. Massey V, Wallner KE: Patterns of second recurrence of malignant astrocytomas. Int J Radiat Oncol Biol Phys 1990, 18:395-398.
10. Liang BC, Thornton AF, Sandler HM, Greenberg HS: Malignant astrocytoma: focal tumor recurrence after focal external beam radiation therapy. J Neurosurg 1991, 75:559-563.
11. Hoegler DB, Davey P: A prospective study of short course radiotherapy in elderly patients with malignant glioma. J Neurooncol 1997, 33:201-204.
12. Liang BC, Liang DM: Primary central nervous system neoplasms. In Practical Neurology. Edited by Biller J. Philadelphia: JB Lippincott; 1997:580-588.
13. Ford JM, Stenning SP, Boote DJ, Counsell R, Falk SJ, Flavin A, Laurence VM, Bleehen NM: A short fractionation radiotherapy treatment for poor prognosis patients with high grade glioma. Clin Oncol (R Coll Radiol) 1997, 9:20-24.
14. Kleinberg L, Slick T, Enger C, Grossman S, Brem H, Wharam MD: Short course radiotherapy is an appropriate option for most malignant glioma patients. Int J Radiat Oncol Biol Phys 1997, 38:31-36.
15. Castro JR, Phillips TR, Prados M, Gutin P, Larson DA, Petti PL, Daftari IK, Collier JM, Lillis-Hearne P: Neon heavy charged particle radiotherapy of glioblastoma of the brain. Int J Radiat Oncol Biol Phys 1997, 38:257-261.
16. Pickles T, Goodman GB, Rheaume DE, Duncan GG, Fryer CJ, Bhimji S, Ludgate C, Syndikus I, Graham P, Dimitrov M, Bowen J: Pion radiation for high grade astrocytoma: results of a randomized study. Int J Radiat Oncol Biol Phys 1997, 37:491-497.
17. Sneed PK, McDermott MW, Gutin PH: Interstitial brachytherapy procedures • for brain tumors. Semin Surg Oncol 1997, 13:157-166. Reports of University of California, San Francisco data using brachytherapy in glial tumors, with listing and comparison with other brachytherapy studies.
18. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan M: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Nat Acad Sci U S A 1992, 89:7491-7495.
19. Boisserie G, Cornu P, Dormont D, Sahel M, Hardiman C, Tep B, Mandin AM, Barret C, Faillot T, Delattre JY, et al.: Iridium 192 brachyterhapy of supra-tentorial high grade glioma recurring in irradiated areas: technique and preliminary results of the Pitie-Salpetriere hospital group. Bull Cancer Radiother 1996, 83:144-152.
20. Hannun YA: Apoptosis and the dilemma of cancer chemotherapy. Blood 1997, 89:1845-1857.
21. Soloway AH, Barth RF, Gahbauer RA, Blue TE, Goodman JH: The rationale • and requirements for the development of boron neutron capture therapy of brain tumors. J Neurooncol 1997, 33:9-18. Excellent discussion of future developmental issues for boron neutron capture therapy.
22. Feinendegen LE: Strategic planning workshop on research needs for • neutron capture therapy. J Neurooncol 1997, 33:179-185. Working issues of boron neutron capture therapy and development as a therapeutic option in glioma.
23. Bucholz TA, Laramore GE, Stelzer KJ, Risler R, Wootton P, Griffin TW: • Boron neutron capture enhanced fast neutron radiotherapy for malignant gliomas and other tumors. J Neurooncol 1997, 33:171-178. Good review of boron neutron capture therapy compared with fast neutron therapy, with potential advantages of each in the treatment of gliomas.
24. Barth RF, Soloway AH, Brugger RM: Boron neutron capture therapy of • brain tumors: past history, current status, and future potential. Cancer Invest 1996, 14:534-550. Very thorough review of the conceptual and practical issues of development of boron neutron capture in human gliomas.
25. Nakagawa Y, Hatanaka H: Boron neutron capture therapy: clinical brain tumor studies. J Neurooncol 1997, 33:105-115.
26. Coderre JA, Elowitz EH, Chadha M, Bergland R, Capala J, Joel DD, Liu HB, Slatkin DN, Chanana AD: Boron neutron capture therapy for glioblastoma multiforme using p-boronophenylalanine and epitheramal neutrons: trial design and clinical results. J Neurooncol 1997, 33:141-152.
27. Urtasun RC, Kinsella TJ, Farnan N, DelRowe JD, Lester SG, Fulton DS: Survival improvement in anaplastic astrocytoma combining external radiation with halogenated pyrimidines: final report of RTOG 86-12, phase I-II study. Int J Radiat Oncol Biol Phys 1996, 36:1163-1167.
28. Fatigante L, Ducci F, Cartein F, Colosimo S, Marini C, Prediletto R, Danesi R, Laddaga M, Del Tacca M, Caciagli P: Carbogen and nicotinamide combined with unconventional radiotherapy in glioblastoma multiforme: a new modality treatment. Int J Biol Phys 1997, 37:499-504.
29. Teicher BA, Holden SA, Northey D, Dewhirst MW, Herman TS; Therapeutic effect of infused fluosol-DA/carbogen with ephedrine, flunarizine, or nitroprusside. Int J Radiat Oncol Biol Phys 1993, 26:103-109.
30. Kohshi K, Kinoshita Y, Terashima H, Konda N, Yokota A, Soejima T: Radiotherapy after hyperbaric oxygenation for malignant gliomas. J Cancer Res Clin Oncol 1996, 122:676-678.
31. . Stewart DJ, Dahrouge S, Agboola O, Girard A: Cranial radiation and concomitant cisplatin and mitomycin-C plus resistance modulators for malignant gliomas. J Neurooncol 1997, 32:161-168.
32. Brandes AA, Rigon A, Zampieri P, Scelzi E, Amista P, Berti F, Rotilio A, Gardiman M, Fiorentino MV: Early chemotherapy and concurrent radiochemotherapy in high grade glioma. J Neurooncol 1996, 30:247-255.
33. Shibamoto Y, Nishimura Y, Tsutsui K, Sasai K, Takahashi M, Abe M Comparison of accelerated hyperfractionated radiotherapy and conventional radiotherapy for supratentorial malignant glioma. Jpn J Clin Oncol 1997, 27:31-36.
34. Grossman SA, Wharam M, Sheidler V, Kleinberg L, Zeltman M, Yue N, Piantadosi S: Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma. J Clin Oncol 1997, 15:2596-2603.
35. Fountzilas G, Karavelis A, Makrantonakis P, Selviaridis P, Tzitzikas J, Kalogera-Fountzila A, Hatzibaloglou A, Karkavelas G, Foroglou G, Tourkantonis A: Concurrent radiation and intracarotid cisplatin infusion in malignant gliomas: a feasibility study. Am J Clin Oncol 1997, 20:138-142.
36. Cavalli L, Liang BC: Mutagenesis, tumorigenicity, and apoptosis: are the mitochondria involved? Mutat Res 1998, in press.
37. Cavalli L, Varella-Garcia L, Liang BC: Changes in tumorigenic phenotype achieved by depletion of mitochondrial DNA. Cell Growth Differ 1997, 8:1189-1198.
38. Liang BC, Ullyatt E: Tyrphostin AG17 chemosensltizes glioma cells to BCNU by a mitochondrially mediated mechanism. Clin Cancer Res 1998, in press.